Report for: Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)

Title	Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
Published in	Trials, January 2021
DOI	10.1186/s13063-020-04976-x
Pubmed ID	33397449
Authors	Pascal Urwyler, Panteleimon Charitos, Stephan Moser, Ingmar A. F. M. Heijnen, Marten Trendelenburg, Reto Thoma, Johannes Sumer, Adrián Camacho-Ortiz, Marcelo R. Bacci, Lars C. Huber, Melina Stüssi-Helbling, Werner C. Albrich, Parham Sendi, Michael Osthoff

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Netherlands	1	50%
Monaco	1	50%

Type	Count	As %
Members of the public	1	50%
Scientists	1	50%

Mendeley readers

The data shown below were compiled from readership statistics for 323 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	323	100%

Readers by professional status	Count	As %
Student > Bachelor	36	11%
Student > Master	31	10%
Researcher	23	7%
Other	14	4%
Librarian	10	3%
Other	44	14%
Unknown	165	51%

Readers by discipline	Count	As %
Medicine and Dentistry	69	21%
Nursing and Health Professions	28	9%
Psychology	8	2%
Pharmacology, Toxicology and Pharmaceutical Science	7	2%
Economics, Econometrics and Finance	6	2%
Other	29	9%
Unknown	176	54%

Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a…